United States Patent 8,334,281: Claim Scope, Exclusivity, Litigation Risk, and Metoclopramide Nasal-Formulation Landscape

U.S. Patent No. 8,334,281 protects stable, preservative-containing metoclopramide nasal solutions. Its strongest coverage requires the combination of metoclopramide, benzalkonium chloride, a buffer, elevated pH or citrate concentration, and color stability after accelerated storage. The patent does not broadly cover all metoclopramide nasal products. A competing product that omits benzalkonium chloride, uses a different preservation system, or falls outside the claimed stability and formulation ranges may avoid literal infringement.

The patent is associated with the metoclopramide nasal spray product Gimoti, approved by the U.S. Food and Drug Administration in 2020 for adults with acute and recurrent diabetic gastroparesis symptoms.[1] The principal commercial risk is an ANDA-based generic challenge to the composition and method claims, not biosimilar competition.

What does U.S. Patent 8,334,281 cover?

The patent covers pharmaceutical compositions and treatment methods for intranasally administered metoclopramide formulations that remain clear to pale yellow during accelerated stability testing.

The independent claim architecture is:

Claim group	Independent claim	Core subject matter
Citrate formulation	1	Metoclopramide, citrate buffer, benzalkonium chloride, citrate concentration of at least about 10 mM, and color stability
Buffered formulation	10	Metoclopramide, a buffer, benzalkonium chloride, pH above about 4.5, and color stability
Benzyl-alcohol formulation	17	Metoclopramide, citrate buffer, benzalkonium chloride, less than about 1% benzyl alcohol, and color stability
Treatment method	14	Intranasal administration of claim 1 composition
Treatment method	27	Intranasal administration of claim 17 composition

The patent’s practical invention is a chemically stable metoclopramide nasal solution. The claims focus on preventing discoloration or degradation associated with a high-concentration metoclopramide formulation and preservative system.

How broad are the independent composition claims?

Claim 1: citrate-buffered formulation

Claim 1 requires all of the following:

Metoclopramide or a pharmaceutically acceptable salt.
A citrate buffer.
Benzalkonium chloride.
A nasal solution.
A clear-to-pale-yellow appearance against USP color standard E, 32.
Stability at 40°C for at least approximately four weeks.
Total citrate concentration of at least approximately 10 millimolar.

The citrate limitation is chemically defined as the combined concentration of citric acid and its ionized citrate species. This drafting approach prevents a manufacturer from avoiding the claim merely by changing the relative proportions of citric acid and citrate salt while maintaining the same total citrate concentration.

Claim 1 does not expressly require a particular metoclopramide concentration, pH, osmolality, or benzalkonium chloride concentration. Those limitations appear in dependent claims 2, 3, 6, 7, and 8.

Claim 10: broader buffer alternative

Claim 10 replaces the citrate requirement with a general buffer requirement but adds a pH limitation. It requires:

Metoclopramide or a pharmaceutically acceptable salt;
A buffer;
Benzalkonium chloride;
A nasal solution;
Stability at 40°C for approximately four weeks; and
A pH above approximately 4.5.

This claim is potentially broader than claim 1 because it is not limited to citrate. Claim 13 lists numerous specific buffer systems, including citrate, phosphate, acetate, borate, maleate, succinate, MES, MOPS, HEPES, and related Good’s buffers.

The scope of claim 10 depends heavily on how “buffer” and the stability limitation are construed. A product using a non-citrate buffer could still fall within claim 10 if its pH and stability satisfy the claim.

Claim 17: benzyl-alcohol formulation

Claim 17 covers a formulation that includes:

Metoclopramide or a pharmaceutically acceptable salt;
A citrate buffer;
Benzalkonium chloride;
Less than approximately 1% benzyl alcohol;
At least approximately 10 mM citrate; and
Four-week color stability at 40°C.

Claim 17 creates a separate protection layer for formulations containing a limited amount of benzyl alcohol. It is not limited to formulations that are completely free of benzyl alcohol.

What dependent claims add to the patent’s scope?

Claims	Added limitation	Commercial significance
2, 3	Starting pH of at least about 4.5 or 5.0	Narrows the formulation toward mildly acidic or near-neutral pH
4	Substantially free of an additional antioxidant	Protects formulations relying on the claimed buffer-preservative system rather than another antioxidant
5	Salt, EDTA, sorbitol, sugar, or flavoring agent	Captures common excipients and taste-modification systems
6	Metoclopramide concentration of about 20%-30% w/v	Covers high-concentration formulations
7	Benzalkonium chloride concentration of about 0.005%-0.05% w/v	Covers typical preservative levels
8	Osmolality of about 500-1,400 mOsm/kg	Covers concentrated nasal solutions
9, 12, 19	Eight-week stability at about 40°C	Provides a stronger stability limitation than the four-week claims
11	Starting pH of at least about 4.6	Intermediate pH limitation
13	Enumerated buffer systems	Expands claim 10 across multiple buffer chemistries
18	Benzyl alcohol concentration of about 0.01%-0.8% w/v	Narrows claim 17 to a defined benzyl-alcohol range
14-16, 27-29	Intranasal treatment of gastroparesis, emesis, delayed emesis, or nausea	Creates method-of-use coverage tied to therapeutic use

The dependent claims are commercially important because they provide fallback positions if a broader independent claim is challenged for anticipation, obviousness, or indefiniteness.

What formulations are protected by U.S. Patent 8,334,281?

The patent is most relevant to a product with the following profile:

Formulation attribute	Claimed range or requirement
Active ingredient	Metoclopramide or pharmaceutically acceptable salt
Dosage form	Nasal solution
Preservative	Benzalkonium chloride
Buffer	Citrate or another listed buffer
Citrate concentration	At least about 10 mM in claims 1 and 17
pH	Above about 4.5 in claim 10; at least about 4.5 or 5.0 in dependent claims
Metoclopramide	About 20%-30% w/v under claim 6 and claim 24
Benzalkonium chloride	About 0.005%-0.05% w/v under claim 7 and claim 25
Benzyl alcohol	Less than about 1% w/v under claim 17
Osmolality	About 500-1,400 mOsm/kg under claim 8 and claim 26
Stability	Clear to pale yellow after four or eight weeks at approximately 40°C
Use	Intranasal treatment of metoclopramide-responsive disorders

The claims do not require a particular container, pump, actuator, dose volume, particle size, or spray pattern. A competing product could therefore infringe even if it uses a different nasal-device configuration, provided the liquid formulation satisfies the claim limitations.

What is the likely scope of literal infringement?

Literal infringement requires every limitation of at least one asserted claim to be present in the accused product or method. For this patent, the most important factual questions are:

Whether the product is a nasal solution rather than a suspension, emulsion, gel, or dry powder.
Whether benzalkonium chloride is present.
Whether the product contains a buffer within the scope of claim 10 or citrate within the scope of claims 1 and 17.
Whether the citrate concentration is at least approximately 10 mM.
Whether the initial pH satisfies the applicable claim.
Whether the product satisfies the 40°C color-stability test.
Whether the formulation contains metoclopramide at a claimed concentration.
Whether the product is administered intranasally for a claimed disorder.

A formulation that contains metoclopramide and benzalkonium chloride but uses no buffer may avoid the independent composition claims. A product with citrate below 10 mM may avoid claims 1 and 17 but could still implicate claim 10 if the formulation contains another buffer and has a pH above approximately 4.5.

How strong is the patent estate for metoclopramide nasal spray?

The estate has meaningful but technically narrow strength.

Strengths

The principal strengths are:

Multiple independent composition claims.
Separate citrate and general-buffer claim strategies.
Method-of-use claims covering intranasal administration.
Stability limitations tied to an objective accelerated-storage condition.
Dependent claims covering concentration, pH, osmolality, preservatives, excipients, and benzyl alcohol.
A formulation architecture closely aligned with the approved product.

The stability limitation may be valuable in litigation because it links the claims to an objective laboratory test. It also creates an evidentiary burden for a challenger, which may need access to formulation samples, manufacturing records, and accelerated-stability data.

Weaknesses

The principal vulnerabilities are:

The claims depend on multiple formulation parameters that may be vulnerable to prior-art combinations.
Terms such as “about,” “substantially free,” “clear to pale yellow,” and “effective amount” may create claim-construction disputes.
Stability at 40°C may be challenged as an inherent property of a known formulation.
Metoclopramide nasal delivery, buffering, preservation, and high-concentration solutions may each have substantial prior-art histories.
The broad buffer list in claim 13 may invite enablement, written-description, or obviousness challenges if the specification does not support the full breadth.
The method claims may be limited by the formulation requirements incorporated through their dependency.

The strongest asserted claims would likely be claims 1, 10, and 17, supported by narrower claims directed to the commercial concentration, preservative level, pH, and stability period.

When does U.S. Patent 8,334,281 lose exclusivity?

The patent’s nominal term is generally calculated from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable statutory extensions. Public patent records associate U.S. Patent 8,334,281 with a nominal expiration in December 2027.[2]

The enforceable expiration date should be determined from the USPTO Patent Center record and the patent’s term-adjustment data. The practical exclusivity date may also be affected by:

Patent-term adjustment;
A terminal disclaimer tied to a related patent;
Patent-term extension, if granted;
Regulatory exclusivity for the approved drug;
Orange Book listing and the timing of any ANDA litigation.

FDA approval does not itself extend the patent term. Regulatory exclusivity and patent exclusivity are separate rights.

What is the FDA and Orange Book status of the related product?

Gimoti is a prescription metoclopramide nasal spray approved under NDA 211976. FDA approved the product in June 2020 for adults with acute and recurrent diabetic gastroparesis symptoms.[1]

The product is a small-molecule drug, not a biologic. Generic competition would proceed through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A biosimilar pathway under section 351(k) of the Public Health Service Act does not apply.

Orange Book-listed patents are relevant because they can trigger a statutory stay if a first-filer submits a valid Paragraph IV certification and the NDA holder or patent owner files suit within the statutory period. The listed patent set should be reviewed in the current FDA Orange Book for NDA 211976 because listings can change through patent expiry, delisting, or FDA administrative action.[3]

What Paragraph IV challenges and generic entry risks exist?

A generic applicant seeking approval of a metoclopramide nasal spray could certify under Paragraph IV that a listed patent is invalid, unenforceable, or not infringed. The main challenge strategies would likely include:

Noninfringement strategy

A generic could attempt to design around the claims by:

Omitting benzalkonium chloride;
Using a non-buffered formulation;
Using a pH at or below the relevant threshold;
Keeping citrate below approximately 10 mM;
Replacing the nasal solution with another dosage form;
Using a different preservative system;
Selecting a formulation that fails the claimed color-stability limitation;
Changing the metoclopramide concentration or osmolality.

Each design-around must be evaluated against the doctrine of equivalents. A small change in citrate concentration or pH may not reliably eliminate risk if the accused formulation performs substantially the same function in substantially the same way.

Invalidity strategy

A Paragraph IV challenger could attack the claims based on:

Anticipation by earlier metoclopramide nasal formulations;
Obviousness based on combining metoclopramide nasal delivery with known buffers and preservatives;
Lack of enablement across the broad buffer list;
Written-description deficiencies for the full range of claimed excipients and stability outcomes;
Indefiniteness of color, approximate ranges, or “substantially free” language;
Failure to demonstrate the claimed stability property across the full scope.

The stability limitation may complicate prior-art analysis. A reference need not expressly report the claimed appearance if the property is inherent, but inherency must be established as necessarily present, not merely possible.

What patent litigation affects metoclopramide nasal spray?

The relevant litigation trigger is an ANDA Paragraph IV filing against an Orange Book-listed patent for the reference product. Filing of an ANDA alone does not establish infringement. The NDA holder or patent owner must file an infringement action within the statutory period to obtain the Hatch-Waxman automatic stay.

A litigation assessment should track:

Event	Consequence
ANDA with Paragraph IV certification	Creates potential patent dispute
Notice letter to NDA holder and patent owner	Starts the statutory response period
Infringement suit within 45 days	Can trigger a 30-month FDA approval stay
Settlement agreement	May establish an agreed generic-entry date
Patent expiration or delisting	Removes the relevant Orange Book barrier
FDA tentative approval	Indicates technical approval but not commercial launch authorization
FDA final ANDA approval	Permits commercial launch subject to enforceable patents and agreements

No generic entrant can be classified as a biosimilar because metoclopramide is a conventional chemical drug.

How does this patent compare with a generic metoclopramide nasal formulation?

Issue	Branded-type formulation covered by the patent	Potential design-around
Active	Metoclopramide	Metoclopramide remains commercially necessary for an equivalent product
Preservative	Benzalkonium chloride	Alternative preservative or preservative-free multidose system
Buffer	Citrate or listed buffer	Different pH-control approach or non-buffered system
pH	Above approximately 4.5 in claim 10	pH at or below threshold, subject to stability and tolerability
Citrate	At least approximately 10 mM	Lower citrate concentration
Stability	Clear to pale yellow at 40°C	Different formulation with separate stability profile
Dosage form	Nasal solution	Suspension, powder, gel, or device-based delivery
Use	Gastroparesis, emesis, nausea	Same clinical use may still raise method-claim issues

The most commercially realistic design-around is likely a formulation that preserves intranasal delivery but changes the preservative and buffer system. That approach may introduce separate regulatory, toxicology, device, and stability risks.

What manufacturing and intellectual-property barriers remain?

The patent is only one barrier. A generic developer must also solve:

High-concentration metoclopramide solubility;
Chemical degradation and discoloration;
Preservative compatibility;
Nasal tolerability;
Pump and container compatibility;
Delivered-dose uniformity;
Microbial-control requirements;
Accelerated and long-term stability;
Bioequivalence for a locally administered nasal product.

Manufacturing know-how may provide practical protection beyond the issued claims. Process parameters, order of addition, pH adjustment, filtration, filling, container closure, and device calibration may be maintained as trade secrets or protected by separate patents.

What is the commercial exposure from the patent?

The patent’s commercial value is concentrated in the approved nasal metoclopramide product rather than the entire metoclopramide market. Oral and injectable metoclopramide products are not necessarily covered because the claims require a nasal solution or intranasal administration.

The relevant exposure is therefore:

Sales of the branded nasal product;
Delay in generic entry caused by listed patents;
Litigation costs and settlement economics;
The feasibility of a noninfringing nasal formulation;
The remaining patent term and any later-expiring continuation or formulation patents.

A later-expiring related patent could be more commercially significant than U.S. Patent 8,334,281 if it covers the approved formulation, device, dosing regimen, or manufacturing process. The complete Orange Book and continuation-family review is necessary to determine whether the 2027 nominal expiration represents the last meaningful U.S. barrier.

Key Takeaways

U.S. Patent 8,334,281 is a formulation and method patent for stable metoclopramide nasal solutions.
Claims 1 and 17 require citrate, benzalkonium chloride, at least approximately 10 mM citrate, and four-week stability at 40°C.
Claim 10 is broader in buffer selection but requires pH above approximately 4.5.
The dependent claims add commercially relevant limitations for pH, metoclopramide concentration, benzalkonium chloride, osmolality, benzyl alcohol, excipients, and eight-week stability.
The patent does not broadly cover every metoclopramide nasal product.
Generic competition would proceed through an ANDA and Paragraph IV certification, not a biosimilar application.
The patent’s nominal expiration is associated with December 2027, subject to USPTO term adjustments, terminal disclaimers, and any applicable extensions.
The strongest design-around options involve changing the preservative, buffer, citrate concentration, pH, or dosage form.
Commercial risk depends on the full Orange Book listing and related continuation or formulation patents, not this patent alone.

FAQs

Does U.S. Patent 8,334,281 cover oral metoclopramide tablets?

No. The asserted composition claims require a nasal solution, and the method claims require intranasal administration.

Can a generic use citrate and avoid the patent?

Potentially, but only if the product avoids every limitation of the asserted claim. Citrate at below approximately 10 mM may avoid claims 1 and 17, but claim 10 could remain relevant if the product contains a buffer, benzalkonium chloride, pH above approximately 4.5, and the claimed stability.

Does removing benzalkonium chloride eliminate patent risk?

It can eliminate a key limitation because the independent composition claims require benzalkonium chloride. The formulation may still implicate other patents, continuation claims, or the doctrine of equivalents.

Is the USPTO patent expiration date the same as the FDA exclusivity date?

No. Patent expiration is governed by patent-term rules. FDA exclusivity is a separate regulatory right and may expire earlier or later depending on the applicable exclusivity period.

Is a metoclopramide nasal spray eligible for biosimilar competition?

No. Metoclopramide is a small-molecule active ingredient. A competing product would generally use the ANDA pathway rather than the biosimilar pathway.

References

U.S. Food and Drug Administration. (2020). FDA approves first nasal spray for treatment of symptoms associated with gastroparesis. https://www.fda.gov
United States Patent and Trademark Office. (2012). U.S. Patent No. 8,334,281, stable metoclopramide formulations. https://patents.google.com/patent/US8334281
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
Manual of Patent Examining Procedure, Chapter 2700, Patent Term. United States Patent and Trademark Office. https://www.uspto.gov/web/offices/pac/mpep/mpep-2700.html

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes	8,334,281	⤷ Start Trial	Y			NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2780485	⤷ Start Trial
Canada	2984736	⤷ Start Trial
Canada	3155873	⤷ Start Trial
Canada	3224872	⤷ Start Trial
Denmark	2376075	⤷ Start Trial
European Patent Office	2376075	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,334,281

Which drugs does patent 8,334,281 protect, and when does it expire?

Summary for Patent: 8,334,281